GenFleet Therapeutics (Shanghai) (HAM:Y3L) EPS (Basic): €-0.60 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:Y3L GenFleet Therapeutics (Shanghai) Inc HAM:Y3L
19 GF Score
Price €2.92
! 3 Warning Signs
View Full Analysis

What is GenFleet Therapeutics (Shanghai) EPS (Basic)?

GenFleet Therapeutics (Shanghai) HAM:Y3L -2.80% 19 EPS (Basic) is €-0.60 as of Dec. 2025. GuruFocus rates HAM:Y3L with a GF Score™ of 19/100. The stock has 3 warning signs investors should review.

GenFleet Therapeutics (Shanghai)'s basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was €-0.36. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.60.

GenFleet Therapeutics (Shanghai)'s EPS (Diluted) for the six months ended in Dec. 2025 was €-0.36. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.60.

GenFleet Therapeutics (Shanghai)'s EPS without NRI for the six months ended in Dec. 2025 was €-0.36. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.60.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

GenFleet Therapeutics (Shanghai)  (HAM:Y3L) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

GenFleet Therapeutics (Shanghai) EPS (Basic) Related Terms

GenFleet Therapeutics (Shanghai) EPS (Basic) Historical Data

* Premium members only.

The historical data trend for GenFleet Therapeutics (Shanghai)'s EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GenFleet Therapeutics (Shanghai) EPS (Basic) Chart

GenFleet Therapeutics (Shanghai) Annual Data
Trend Dec23 Dec24 Dec25
EPS (Basic)
-0.21 -0.28 -0.74

GenFleet Therapeutics (Shanghai) Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) 0.00 -0.18 -0.10 -0.24 -0.36
HAM:Y3L
19GF Score
GenFleet Therapeutics (Shanghai) Inc HAM:Y3L
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GenFleet Therapeutics (Shanghai) EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

GenFleet Therapeutics (Shanghai)'s Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-217.59-0)/295.808
=-0.74

GenFleet Therapeutics (Shanghai)'s Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-132.883-0)/370.367
=-0.36

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-0.60 mean?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a EPS (Basic) of €-0.60 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on GenFleet Therapeutics (Shanghai) and its competitors.
Is GenFleet Therapeutics (Shanghai)'s EPS (Basic) too high?
GenFleet Therapeutics (Shanghai)'s current EPS (Basic) is €-0.60. Overall, GenFleet Therapeutics (Shanghai) has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does GenFleet Therapeutics (Shanghai)'s EPS (Basic) compare to VRTX and REGN?
GenFleet Therapeutics (Shanghai)'s EPS (Basic) of €-0.60 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. GenFleet Therapeutics (Shanghai)'s current EPS (Basic) is €-0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenFleet Therapeutics (Shanghai) stock overvalued right now?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a current EPS (Basic) of €-0.60. The current EPS (Basic) is €-0.60. GenFleet Therapeutics (Shanghai)'s overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For GenFleet Therapeutics (Shanghai) (HAM:Y3L), the current EPS (Basic) is €-0.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GenFleet Therapeutics (Shanghai) Business Description

Other Exchanges 02595:Hong Kong
Address 1206 Zhangjiang Road, Floors 2nd, 3rd, 4th, and 5th, Building 8, Shanghai Pilot Free Trade Zone, Shanghai, CHN, 201203
GenFleet Therapeutics (Shanghai) Inc Company is a clinical-stage biotechnology company. The Company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment.
19GF Score

Get the complete analysis for HAM:Y3L

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.92
Price